Basalog Refil 100 IU/ml 3 ml Cartridge

Basalog Refill Solution for Injection contains insulin to type 1and type 2 diabetes mellitus in both adults and children. It works by replacing the insulin that is produced in the body. It also stops the liver from producing more sugar. Its active ingredient is Insulin Glargine in the concentration of 100IU/ml. Doctor strictly prescribed this medicine as the first line therapy as it provide steady, long lasting release of insulin that helps maintain stable blood sugar levels.

Provide Insulin; control blood sugar

Basalog Refill Solution for Injection contains side effects like other medication. Consult the doctor if the symptoms persist. Here are some common symptoms that should be noticed:
● Allergic reaction
● Rash
● Edema (swelling)
● Injection site reactions (pain, swelling and redness)
● Itching weight pain
● Weight gain
● Hypoglycemia (Low blood glucose level)
● Lipodystrophy ( skin thickening at the injection site)

Basalog Refill Solution for Injection is an insulin. It should be taken on upper arm, thigh or abdomen, rotate the injection site every time to prevent skin from irritation or lypodystrophy. Do not double the dose on the missed one as it may increase the risk of side effects. If you miss a dose follow the doctor instruction on how to proceed and do not make any adjustments on your own.

Basalog Refill solution for Injection produce insulin. It helps to provide insulin to type 1 and type 2 diabetic patients to control high blood (glucose) levels. This allows the glucose into your cells so the body can use it for energy, while also reducing the amount of glucose produced by the liver. By maintaining stable insulin levels, it helps prevent complications associated with uncontrolled diabetes.

• Bolli, G. B., & Owens, D. R. (2000). Insulin glargine. The Lancet, 356(9228), 443-445.
• Wang, F., Carabino, J. M., & Vergara, C. M. (2003). Insulin glargine: a systematic review of a long-acting insulin analogue. Clinical therapeutics, 25(6), 1541-1577.
• Gillies, P. S., Figgitt, D. P., & Lamb, H. M. (2000). Insulin glargine. Drugs, 59(2), 253-260.
• Campbell, R. K., White, J. R., Levien, T., & Baker, D. (2001). Insulin glargine. Clinical therapeutics, 23(12), 1938-1957.
• Swinnen, S. G., Simon, A. C., Holleman, F., Hoekstra, J. B., & DeVries, J. H. (2011). Insulin detemir versus insulin glargine for type 2 diabetes mellitus. The Cochrane database of systematic reviews, 2011(7), CD006383.